Relevance of platelet factor four (PF4) plasma levels in multiple sclerosis
| Autor: | Giovanni D'Andrea, Cananzi Ar, Francesco Grigoletto, Moreno Toldo, F. Ferro-Milone, Francesca Meneghini, F. Bortolon |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Adult
Male medicine.medical_specialty Multiple Sclerosis Platelet Aggregation Prostacyclin Stimulation Platelet Factor 4 Internal medicine Humans Medicine Platelet Platelet activation Aspirin Hematology business.industry Multiple sclerosis General Medicine beta-Thromboglobulin medicine.disease Endocrinology Neurology Immunology Female Neurology (clinical) business Platelet factor 4 medicine.drug |
| Zdroj: | Acta Neurologica Scandinavica. 76:79-85 |
| ISSN: | 1600-0404 0001-6314 |
| DOI: | 10.1111/j.1600-0404.1987.tb03550.x |
| Popis: | In order to study the role of platelets in Multiple Sclerosis (MS) we assessed, in a group of patients during a quiescent phase of the disease, the plasma levels of beta-thromboglobulin (beta-TG) and platelet factor four (PF4) both in absence of treatment and during administration of aspirin (ASA) at the dose of 50 mg/daily. In the MS patients studied, the basal plasma levels of beta-TG and PF4 were significantly higher than in control subjects. The increase in the beta-TG plasma levels occurred independently of the age, sex and severity of the disease, whereas the modification in the PF4 plasma levels was significantly correlated with the severity of the disease. Administration to the patients of ASA, at the dose that does not affect prostacyclin production, determined a decrease of beta-TG in 77% of the patients. Mean PF4 plasma levels remained unchanged. These results suggest that PF4 in the plasma of MS patients may originate not only from the platelets but also from the mast cells following platelet aggregating factor (PAF) stimulation and immunocomplex formation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|